《Ｏｘｆｏｒｄ Ａｄｖａｎｃｅｄ Ｌｅａｒｎｅｒ’ｓ Ｄｉｃｔｉｏｎａｒｙ ｏｆ Ｃｕｒｒｅｎｔ Ｅｎｇｌｉｓｈ》（ 以下简称ＯＡＬＤ） 是英语学习词典的先驱。它是第一部既重视词语释义，又重视词法、句法，配有大量例证的词典。我国英语学习者对其第二、三、四版（ 英汉双解版） 都十分熟悉。１９９５ 年，ＯＡＬＤ 第五次修订再版，又有了新的特色，但仍有不足

评《Oxford Advanced Learner’s Dictionary of Current English》第五版

Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: A review

Targeted protein degradation, using bifunctional small molecules (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches. In this Perspective, the brief history of the field is surveyed from a drug discovery perspective with a focus on the key advances in knowledge which have led to the definition and exemplification of protein degradation concepts and their resulting applications to medicine discovery. The approach has the potential to bring disruptive change to drug discovery; the many potential advantages and outstanding challenges which lie ahead of this technology are discussed.

Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Microemulsion utility in pharmaceuticals: Implications for multi-drug delivery.

Despite U.S. Food and Drug Administration (FDA) approval of over 40 new treatment options for type 2 diabetes since 2005, the latest data from the National Health and Nutrition Examination Survey show that the proportion of patients achieving glycated hemoglobin (HbA1c) <7.0% (<53 mmol/mol) remains around 50%, with a negligible decline between the periods 2003-2006 and 2011-2014. The Healthcare Effectiveness Data and Information Set reports even more alarming rates, with only about 40% and 30% of patients achieving HbA1c <7.0% (<53 mmol/mol) in the commercially insured (HMO) and Medicaid populations, respectively, again with virtually no change over the past decade. A recent retrospective cohort study using a large U.S. claims database explored why clinical outcomes are not keeping pace with the availability of new treatment options. The study found that HbA1c reductions fell far short of those reported in randomized clinical trials (RCTs), with poor medication adherence emerging as the key driver behind the disconnect. In this Perspective, we examine the implications of these findings in conjunction with other data to highlight the discrepancy between RCT findings and the real world, all pointing toward the underrealized promise of FDA-approved therapies and the critical importance of medication adherence. While poor medication adherence is not a new issue, it has yet to be effectively addressed in clinical practice-often, we suspect, because it goes unrecognized. To support the busy health care professional, innovative approaches are sorely needed.

https://care.diabetesjournals.org/content/diacare/early/2017/08/10/dc16-1974.full.pdf

Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control

Objective
To explore and evaluate the most common factors causing therapeutic non-compliance.

/pdf/factors-affecting-therapeutic-compliance-a-review-from-the-2dvyfkvlx9.pdf

Vernon Min Sen Oh

Papers

Factors affecting therapeutic compliance: A review from the patient's perspective.